Fiduciary Financial Services of The Southwest Inc. TX increased its stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 2.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,200 shares of the medical research company’s stock after buying an additional 50 shares during the period. Fiduciary Financial Services of The Southwest Inc. TX’s holdings in Laboratory Corporation of America Holdings were worth $339,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Diversified Trust Co boosted its stake in shares of Laboratory Corporation of America Holdings by 2.3% in the first quarter. Diversified Trust Co now owns 2,181 shares of the medical research company’s stock valued at $313,000 after buying an additional 50 shares during the period. State of Alaska Department of Revenue boosted its stake in shares of Laboratory Corporation of America Holdings by 43.2% in the first quarter. State of Alaska Department of Revenue now owns 19,536 shares of the medical research company’s stock valued at $2,802,000 after buying an additional 5,898 shares during the period. Quantitative Systematic Strategies LLC boosted its stake in shares of Laboratory Corporation of America Holdings by 32.8% in the first quarter. Quantitative Systematic Strategies LLC now owns 5,399 shares of the medical research company’s stock valued at $775,000 after buying an additional 1,334 shares during the period. Coastline Trust Co boosted its stake in shares of Laboratory Corporation of America Holdings by 57.4% in the first quarter. Coastline Trust Co now owns 3,810 shares of the medical research company’s stock valued at $547,000 after buying an additional 1,390 shares during the period. Finally, DnB Asset Management AS acquired a new stake in shares of Laboratory Corporation of America Holdings during the first quarter valued at approximately $9,264,000. 91.64% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Corporation of America Holdings (NYSE:LH) opened at 156.50 on Tuesday. Laboratory Corporation of America Holdings has a 12 month low of $119.51 and a 12 month high of $164.22. The firm’s 50 day moving average is $155.49 and its 200-day moving average is $144.59. The firm has a market cap of $15.93 billion, a price-to-earnings ratio of 21.92 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.40 by $0.07. The firm had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company earned $2.36 earnings per share. On average, equities analysts forecast that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Fiduciary Financial Services of The Southwest Inc. TX Boosts Position in Laboratory Corporation of America Holdings (LH)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/15/fiduciary-financial-services-of-the-southwest-inc-tx-boosts-position-in-laboratory-corporation-of-america-holdings-lh.html.

Several research analysts have recently weighed in on LH shares. ValuEngine lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. Jefferies Group LLC lowered their price objective on shares of Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating on the stock in a research note on Friday, April 28th. Barclays PLC boosted their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Zacks Investment Research lowered shares of Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. Finally, BidaskClub upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Laboratory Corporation of America Holdings currently has a consensus rating of “Buy” and an average target price of $159.00.

In related news, SVP Lance Berberian sold 3,613 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total transaction of $505,241.92. Following the completion of the transaction, the senior vice president now owns 5,789 shares of the company’s stock, valued at $809,533.76. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Lisa J. Uthgenannt sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $160.00, for a total transaction of $800,000.00. The disclosure for this sale can be found here. Insiders sold 14,581 shares of company stock valued at $2,256,899 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.